Prot #70033093AFL3002: (LIBREXIA-AF) A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fib

Project: Research project

Project Details

StatusActive
Effective start/end date11/27/23 → 9/15/27

Funding

  • Quintiles, Inc. (Prot # 70033093AFL3002 // Prot # 70033093AFL3002)
  • Janssen Research & Development, LLC (Prot # 70033093AFL3002 // Prot # 70033093AFL3002)